InterAx Biotech

📍 Villigen, Switzerland🗓 Founded 2016👥 17 employees💰 Last funded Jul 2022
Biotechnology Research🌐 interaxbiotech.com
Website LinkedIn
The company, a spin-out of ETH Zurich and the Paul Scherrer Institute, Switzerland, uses high throughput biochemical screening of compounds integrated into an artificial intelligence and cell pathways mathematical modeling process. This platform unlocks previously intractable targets, shortens timelines for drug discovery from years to months and reduces risks. The company focuses on the generation and optimization of drugs which trigger a specific and well characterized effect on signaling pathways, thus leading to higher therapeutic efficacy and reduced risk of toxicity. The company is specialized in GPCR drug discovery and covers hit-generation, hit- to-lead and lead optimization for all targets including orphan GPCRs. InterAx AG has a highly experienced and dedicated team of scientists specialized in AI, mathematical models of signaling pathways, cellular pharmacology and computational chemistry.
3
Total investors
0
Early stage
2
Mid stage
1
Late stage
2016
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Switzerland
3
Investor activity2019–2022 · investors recorded per year
2019220221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in InterAx Biotech?
InterAx Biotech has 3 investors on record on gritt.io, 2 mid-stage and 1 late-stage investors.
When did InterAx Biotech last raise funding?
The most recent investment in InterAx Biotech recorded on gritt.io was in July 2022.
When was InterAx Biotech founded?
InterAx Biotech was founded in 2016.
What industry is InterAx Biotech in?
InterAx Biotech operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is InterAx Biotech based?
InterAx Biotech is headquartered in Villigen, Switzerland.